PDCD1 and metastatic neoplasm: Although underlying chronic liver disease may inhibit the efficacy of anticancer therapies, including anti–PD-1 therapy, 4-MU and 4-MUG have the potential to suppress steatotic liver–associated metastatic tumor growth.